Fig. 6.

Effect of the DRP1 inhibitor Midiv-1 on the hyperglycemia-induced heart sensitivity to IR. (A) Control rats (NG) and STZ-treated rats (HG) were treated or not with Mdivi-1 (1.2 mg/kg; intraperitoneal injection), 24 h and 1 h before in vivo IR (30 min of ischemia followed by 2 h of reperfusion). (B) Bood glucose levels before IR (N = 4–6 rats/group; *p < 0.05 NG vs. HG; two-way ANOVA). (C) Animal survival rate (no cardiac arrest before the reperfusion end) during IR (N = 4–6 rats/group). (D) Representative ECG recording before ischemia (baseline), after 30 min of ischemia (coronary artery ligation), and after reperfusion (90 min) in NG and HG rats pre-treated or not with Mdivi-1 (1.2 mg/kg; intraperitoneal injection) 24 h and 1 h before coronary artery ligation. (E) QTc values recorded at baseline and after 90 min reperfusion (N = 4–6 rats/group; *p < 0.05 NG vs. HG post-IR; repeated two-way ANOVA). (F) Representative transverse sections of triphenyl tetrazolium chloride-stained hearts from NG or HG rats treated or not with Mdivi-1 (1.2 mg/kg). The deep red visible area represents the area at risk (AAR), the white area is the infarcted area, and the blue area indicates non-ischemic tissue. (G) AAR percentage, calculated as the AAR to LV size ratio, in each group (N = 4–6 hearts/group). (H) Percentage of infarct size, calculated as the infarcted area to the AAR ratio in each group (N = 4–6 rats/group; $p < 0.05 Mdivi-1 effect; two-way ANOVA). (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)